Liver News and Research

RSS

Statins to carry revised warning labels: FDA

The U.S. FDA announced today that they would add additional safety warnings to the labels on statins, a class of drugs that lower cholesterol. Statins – with brand names Lipitor, Crestor and Zocor work by inhibiting the enzyme that plays a big part in the liver's production of cholesterol.

29 Feb 2012

Wiley-Blackwell to publish 44 new important journals in 2012

In 2012 Wiley-Blackwell, the Scientific, Technical, Medical, and Scholarly publishing business of John Wiley & Sons, Inc., will begin publishing 44 titles new to its journal program, including 16 new launches and 40 journals published in collaboration with societies or other organizations.

29 Feb 2012

Insights into how fructose may contribute to development of obesity, diabetes

A group of scientists from across the world have come together in a just-published study that provides new insights into how fructose causes obesity and metabolic syndrome, more commonly known as diabetes.

28 Feb 2012

GE Healthcare Discovery MR750w 3.0T scanner installed at BRMI

Patients and clinicians alike are celebrating the newest arrival at BRMI@ Dyker Heights of an innovative GE Healthcare Discovery MR750w 3.0T scanner.

27 Feb 2012

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

27 Feb 2012

First patients in Germany treated with Delcath Hepatic CHEMOSAT Delivery System

Delcath Systems, Inc., announced today that the first patients in Germany have been treated with the Delcath Hepatic CHEMOSAT Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the Company announced with the hospital in December 2011.

27 Feb 2012

H2S transforms dental pulp stem cells into liver cells

Japanese scientists have found that the odorous compound responsible for halitosis - otherwise known as bad breath - is ideal for harvesting stem cells taken from human dental pulp.

27 Feb 2012

New method can predict whether Tylenol-poisoning patients need liver transplant

University of Utah mathematicians developed a set of calculus equations to make it easier for doctors to save Tylenol overdose patients by quickly estimating how much painkiller they took, when they consumed it and whether they will require a liver transplant to survive.

27 Feb 2012

Exelixis announces cabozantinib preclinical data on pancreatic cancer

Exelixis, Inc. today announced the company's lead compound, cabozantinib, is highlighted in a new peer-reviewed publication demonstrating that simultaneous inhibition of MET and VEGF signaling reduces tumor invasiveness and metastasis in preclinical models of pancreatic cancer.

26 Feb 2012

Article in journal Science proposes new look on killer diseases

The immune system protects from infections by detecting and eliminating invading pathogens. These two strategies form the basis of conventional clinical approaches in the fight against infectious diseases.

24 Feb 2012

Can-Fite receives FDA Orphan Drug Status for CF102 to treat hepatocellular carcinoma

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate, CF102, for the treatment of hepatocellular carcinoma.

23 Feb 2012

Elevated levels of two TLRs can trigger heart disease and diabetes

UC Davis scientists have uncovered a key suspect in the destructive inflammation that underlies heart disease and diabetes. The new research shows elevated levels of a receptor present on leucocytes of the innate immune response in people at risk for these chronic diseases.

23 Feb 2012

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Onyx Pharmaceuticals, Inc. today reported its financial results for the full year and fourth quarter 2011. Onyx reported non-GAAP net income of $42.0 million, or $0.66 per diluted share, for the full year 2011 compared to non-GAAP net income of $39.2 million, or $0.63 per diluted share, for the same period in 2010.

23 Feb 2012

First-ever comparative analysis of antimalarial medicines at every step of the parasite's life cycle

MMV and partners have completed the first-ever comparative analysis of all currently available and in-development antimalarials in terms of the steps they target in the parasite's lifecycle. This information provides the missing pieces of the puzzle needed to develop future medicines able to block transmission of the parasite from person to person.

23 Feb 2012

Routine hepatitis C testing of the middle aged could save thousands of lives: CDC report

Increasing number of people are dying of damaged livers due to hepatitis C infection. Federal health officials are considering whether anyone born between 1945 and 1965 should get a one-time blood test to check if they are harboring the dangerous virus. Two-thirds of people with hepatitis C are in this age group, most unaware that a virus that takes a few decades to do its damage has festered since their younger days.

22 Feb 2012

IDOM researchers overturn textbook view of liver metabolism

A team led by researchers from the Institute for Diabetes, Obesity and Metabolism (IDOM) at the Perelman School of Medicine, University of Pennsylvania, has overturned a "textbook" view of what the body does after a meal.

22 Feb 2012

EMA grants positive scientific opinion for Pyramax to treat malaria

Pyramax-, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. This once daily, 3-day treatment is indicated for acute, uncomplicated Plasmodium falciparum and blood-stage Plasmodium vivax malaria in adults and children over 20 kg.

22 Feb 2012

Telomerase reactivation in malignant cells after genomic instability causes cancer progression

Inhibiting telomerase, an enzyme that rescues malignant cells from destruction by extending the protective caps on the ends of chromosomes, kills tumor cells but also triggers resistance pathways that allow cancer to survive and spread, scientists report in the Feb. 17 issue of Cell.

21 Feb 2012

New triple-therapies found cost-effective for chronic hepatitis C patients with advanced liver disease

A towering $60,000 bill, a year of fierce, flu-like symptoms and a running risk of depression are among the possible costs of two new hepatitis C treatments. But according to Stanford University health policy researchers, they might be worth it.

21 Feb 2012

Some answers about prescription psychiatric drugs

The circumstances of Whitney Houston's demise have dominated headlines and search trends since news outlets first reported of her death. Her struggle with addiction was covered extensively by the media, and even discussed candidly by Houston herself during several high-profile interviews.

20 Feb 2012